Galectin-3 and L1 retrotransposons in human breast carcinomas.

Abstract:

:Galectin-3 is a galactoside binding protein found at elevated levels in a wide variety of neoplastic cells and thought to be involved in cognitive cellular interactions during transformation and metastasis. Previously, we have shown that introduction of human galectin-3 (Mr 31,000) cDNA into the human breast cancer cells BT-549 which are galectin-3 null and non-tumorigenic in nude mice resulted in the establishment of four galectin-3 expressing clones. Three of them acquired tumorigenicity when inoculated in the mammary fat pad of nude mice. Here, we questioned what is the molecular difference between the nude mouse tumorigenic and non-tumorigenic galectin-3 expressing BT-549 cell clones. Differential display analysis and Northern blotting revealed that, unlike the tumorigenic clones, neither the parental cells nor the non-tumorigenic clone expressed a 6.5 Kb transcript. A 607 bp PCR (polymerase chain reaction) product from the differentially displayed mRNA revealed a 93% sequence homology with the human L1 retrotransposon previously suggested to play a role in the pathobiology of some breast cancers. In addition, we show that the two gene products, i.e., galectin-3 and L1, are co-expressed in breast carcinoma specimens and in other nude mouse tumorigenic cell lines.

authors

Nangia-Makker P,Sarvis R,Visscher DW,Bailey-Penrod J,Raz A,Sarkar FH

doi

10.1023/a:1005913810250

subject

Has Abstract

pub_date

1998-05-01 00:00:00

pages

171-83

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

49

pub_type

杂志文章
  • Rho proteins and cancer.

    abstract::The Rho family of GTPases has been intensively studied for their roles in signal transduction processes leading to cytoskeletal-dependent responses, including cell migration and phagocytosis. In addition, they are important regulators of cell cycle progression and affect the expression of a number of genes, including ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/B:BREA.0000018423.47497.c6

    authors: Ridley AJ

    更新日期:2004-03-01 00:00:00

  • Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

    abstract:BACKGROUND:Gemcitabine (G) and vinorelbine (V) have favorable safety profile and antitumor activity in metastatic breast cancer. To exploit their different mechanism of action and lack of overlapping toxicity, we performed a phase I and II study of G and V in combination. PATIENTS AND METHODS:Fifty-three patients with...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1013034311284

    authors: Mariani G,Tagliabue P,Zucchinelli P,Brambilla C,Demicheli R,Villa E,Marchianò A,Valagussa P,Bonadonna G,Gianni L

    更新日期:2001-12-01 00:00:00

  • Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase.

    abstract::Resveratrol is a natural polyphenolic compound and has been shown to exhibit cardio-protective as well as anti-neoplastic effects on various types of cancers. However, the exact mechanism of its anti-tumor effect is not clearly defined. Resveratrol has been shown to have strong hypolipidemic effect on normal adipocyte...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1300-6

    authors: Pandey PR,Okuda H,Watabe M,Pai SK,Liu W,Kobayashi A,Xing F,Fukuda K,Hirota S,Sugai T,Wakabayashi G,Koeda K,Kashiwaba M,Suzuki K,Chiba T,Endo M,Fujioka T,Tanji S,Mo YY,Cao D,Wilber AC,Watabe K

    更新日期:2011-11-01 00:00:00

  • The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer.

    abstract:PURPOSE:Many women with early-onset breast cancer experience adverse psychological sequelae which impact on their quality of life. We sought to correlate levels of anxiety and cancer-related distress in women with breast cancer shortly after surgery and one year after treatment with the estimated risk of death. METHOD...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05992-w

    authors: Metcalfe KA,Candib A,Giannakeas V,Eisen A,Poll A,McCready D,Cil T,Wright FC,Armel S,Ott K,Sun P,Narod SA

    更新日期:2020-11-10 00:00:00

  • Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.

    abstract::The prognostic significance of estradiol (ER) and progesterone receptors (PgR) for survival from relapse has been studied in two groups of breast cancer patients: group 1, 35 patients in whom receptor levels were measured at the time of mastectomy; group II, 49 patients in whom receptor levels were measured at the tim...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805988

    authors: Bonneterre J,Horner D,Peyrat JP,Vandewalle B,Cambier L,Demaille A

    更新日期:1985-01-01 00:00:00

  • Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer.

    abstract::Few studies have assessed the agreement between subjects' self-report and medical records among patients with breast cancer (BC), and none has addressed this issue in low-income women with BC. We assessed the level of agreement between self-report and medical records data for key BC treatment and prognostic characteri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0447-5

    authors: Liu Y,Diamant AL,Thind A,Maly RC

    更新日期:2010-02-01 00:00:00

  • Exercise during puberty and NMU induced mammary tumorigenesis in rats.

    abstract::Previously we have shown that exercising rats prior to administration of 50 mg NMU/kg (high dose) significantly decreased tumor multiplicity, but not incidence or latency. We hypothesized that the dose of NMU saturated the system such that the exercise intervention was overshadowed. Therefore, the purpose of this inve...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005838721890

    authors: Whittal-Strange KS,Chadan S,Parkhouse WS

    更新日期:1998-01-01 00:00:00

  • Ethanol enhances erbB-mediated migration of human breast cancer cells in culture.

    abstract::Growth factor systems (ligands and their receptors) are targets of ethanol toxicity. Inasmuch as alcohol consumption may increase the risk and development of breast cancer, we hypothesize that ethanol enhances cell migration by up-regulating the activities of erbB receptors. Of the three tested breast cancer cell line...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006436315284

    authors: Luo J,Miller MW

    更新日期:2000-09-01 00:00:00

  • Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.

    abstract::Compelling evidence about the differences in the biology and behavior of invasive breast cancer between African-American (AA) and White-American (WA) women motivate inquiry into comparing the clinicopathology of non-invasive breast cancer (ductal carcinoma in situ, DCIS). AA and WA women diagnosed with their first pri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1742-5

    authors: Stark A,Stapp R,Raghunathan A,Yan X,Kirchner HL,Griggs J,Newman L,Chitale D,Dick A

    更新日期:2012-01-01 00:00:00

  • Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

    abstract::Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0469-z

    authors: Brown M,Bauer K,Pare M

    更新日期:2010-02-01 00:00:00

  • Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4985-6

    authors: Guestini F,Ono K,Miyashita M,Ishida T,Ohuchi N,Nakagawa S,Hirakawa H,Tamaki K,Ohi Y,Rai Y,Sagara Y,Sasano H,McNamara KM

    更新日期:2019-01-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract::This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-004-4384-z

    authors: Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期:2004-11-01 00:00:00

  • Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

    abstract:BACKGROUND:Women affected with breast cancer who carry a BRCA1 or BRCA2 (BRCA1/2) mutation are at risk of developing contralateral breast cancer. To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in additio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9423-5

    authors: Graves KD,Peshkin BN,Halbert CH,DeMarco TA,Isaacs C,Schwartz MD

    更新日期:2007-09-01 00:00:00

  • Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.

    abstract::Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0244-6

    authors: Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

    更新日期:2010-01-01 00:00:00

  • Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.

    abstract::The contribution of BRCA1 and BRCA2 to breast cancer incidence in Brazil has not yet been explored. In order to estimate the proportion of breast cancers due to BRCA1 and BRCA2 mutations in Brazil, we conducted a study of unselected breast cancer patients from Rio de Janeiro, Brazil. We enrolled 402 women with breast ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9378-6

    authors: Gomes MC,Costa MM,Borojevic R,Monteiro AN,Vieira R,Koifman S,Koifman RJ,Li S,Royer R,Zhang S,Narod SA

    更新日期:2007-07-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract::Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666210

    authors: LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期:1994-01-01 00:00:00

  • The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.

    abstract:BACKGROUND:The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women. METHODS:As part of a continuing med...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9031-9

    authors: Gainford MC,McCready D,Clemons M

    更新日期:2006-04-01 00:00:00

  • Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.

    abstract::The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-013-2825-2

    authors: de Dueñas EM,Hernández AL,Zotano AG,Carrión RM,López-Muñiz JI,Novoa SA,Rodríguez AL,Fidalgo JA,Lozano JF,Gasión OB,Carrascal EC,Capilla AH,López-Barajas IB,Mateu MM,de Ceballos Reyna MH,Ferrando AO,Jañez NM,Ballerini VC

    更新日期:2014-02-01 00:00:00

  • Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

    abstract::The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-010-1202-7

    authors: Khoshnoud MR,Löfdahl B,Fohlin H,Fornander T,Stål O,Skoog L,Bergh J,Nordenskjöld B

    更新日期:2011-04-01 00:00:00

  • Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System.

    abstract::The Breast Imaging Reporting and Data System (BI-RADS) was introduced in 1993 to standardize the interpretation of mammograms. Though many studies have assessed the validity of the system, fewer have examined its reliability. Our objective is to identify predictors of reliability as measured by the kappa statistic. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0770-x

    authors: Antonio AL,Crespi CM

    更新日期:2010-04-01 00:00:00

  • The effects of TGF-alpha and 17 beta-estradiol on polyphosphoinositide metabolism in MCF-7 breast cancer cells.

    abstract::The mechanism by which transforming growth factor-alpha (TGF-alpha) stimulates breast cancer cell proliferation is largely unknown. Furthermore, its potential role as an autocrine effector of estradiol-17 beta (E2)-stimulated growth of hormone-dependent mammary tumors remains controversial. Transient changes in phosph...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01832359

    authors: Etindi RN,Manni A,Martel J

    更新日期:1992-01-01 00:00:00

  • Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.

    abstract:PURPOSE:Body composition parameters including low muscle mass, muscle attenuation (which reflects muscle quality) and adipose tissue measurements have emerged as prognostic factors in cancer patients. However, knowledge regarding the possibility of excessive muscle loss during specific systemic therapies is unknown. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4574-0

    authors: Rier HN,Jager A,Sleijfer S,van Rosmalen J,Kock MCJM,Levin MD

    更新日期:2018-02-01 00:00:00

  • Atypical ezrin localization as a marker of locally advanced breast cancer.

    abstract::Locally advanced breast cancer (LABC) was initially characterized as a large primary tumor (≥5 cm), associated with or without skin or chest-wall involvement, fixed axillary lymph nodes, or disease spread to the ipsilateral internal mammary or supraclavicular nodes. Since 2002, LABC has been reclassified to include sm...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2017-5

    authors: Arslan AA,Silvera D,Arju R,Giashuddin S,Belitskaya-Levy I,Formenti SC,Schneider RJ

    更新日期:2012-08-01 00:00:00

  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    abstract:BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-008-0057-7

    authors: Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

    更新日期:2009-05-01 00:00:00

  • Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients.

    abstract::The relative amounts of the precursor (52 kDa) and processed (31,27 kDa) forms of cathepsin D have been analyzed by Western blotting in biopsied breast tissue cytosols from 134 lesions from invasive breast cancer patients, 24 lesions from patients with ductal carcinoma in situ (DCIS), 227 lesions from benign breast di...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006394401199

    authors: Riley LB,Lange MK,Browne RJ,Cochrane PJ,Choi IJ,Davis B,Arcona S,Alhadeff JA

    更新日期:2000-03-01 00:00:00

  • Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost.

    abstract::Many patients with metastatic breast cancer receive several types of chemotherapy, although it is recognized that there is a declining probability of response. A major problem confronts oncologists in deciding when to recommend to patients that no further chemotherapy should be given. To address this problem we have a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006123721205

    authors: McLachlan SA,Pintilie M,Tannock IF

    更新日期:1999-04-01 00:00:00

  • Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.

    abstract:PURPOSE:We investigated the oncologic outcomes by intrinsic subtype and age in young breast cancer patients and whether survival differences were related to treatment changes over time. METHODS:A retrospective analysis was performed on 9633 invasive breast cancer patients treated at Asan Medical Center from January 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4331-4

    authors: Yoon TI,Hwang UK,Kim ET,Lee S,Sohn G,Ko BS,Lee JW,Son BH,Kim S,Ahn SH,Kim HJ

    更新日期:2017-09-01 00:00:00

  • Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

    abstract:PURPOSE:This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS:The study comprised 126 index patients who met NCCN clinical criteria and te...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05985-9

    authors: Gomes R,Spinola PDS,Brant AC,Matta BP,Nascimento CM,de Aquino Paes SM,Bonvicino CR,Dos Santos ACE,Moreira MAM

    更新日期:2020-10-30 00:00:00

  • CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

    abstract::We investigated the expression of -CXC chemokine ligand 13 (CXCL13) and its receptor -CXC chemokine receptor 5 (CXCR5) in 98 breast cancer (BC) patients with infiltrating duct carcinoma, out of which 56 were found lymph node metastasis (LNM) positive. Interestingly, co-expression of CXCL13 and CXCR5 showed a significa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2811-8

    authors: Biswas S,Sengupta S,Roy Chowdhury S,Jana S,Mandal G,Mandal PK,Saha N,Malhotra V,Gupta A,Kuprash DV,Bhattacharyya A

    更新日期:2014-01-01 00:00:00

  • Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

    abstract:PURPOSE:Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS:We constructed a Markov model to assess the cost-effectiveness of four diffe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3978-6

    authors: Diaby V,Adunlin G,Ali AA,Zeichner SB,de Lima Lopes G,Kohn CG,Montero AJ

    更新日期:2016-11-01 00:00:00